|
|
News Breaks | | | | February 11, 2013 | | 08:05 EDT |  | ANX | Adventrx initiates QT/QTc clinical study of ANX-188
ADVENTRX Pharmaceuticals announced that it has initiated dosing in a thorough QT/QTc study of ANX-188. The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers. The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial. Sixty subjects will be enrolled. Each subject will receive each of four treatments during each of the four treatment periods. | |
|
News For ANX From The Last 14 Days Check below for free stories on ANX the last two weeks. |
|
|
| There are no results for ANX |
|
|
|
|
|
|
